Zatolmilast is a investigational new drug that is being evaluated to treat fragile X syndrome.[1] It is a PDE4D allosteric inhibitor.[2]

Zatolmilast
Clinical data
Other namesBPN-14770
Legal status
Legal status
  • Investigational
Identifiers
  • 2-[4-[[2-(3-chlorophenyl)-6-(trifluoromethyl)pyridin-4-yl]methyl]phenyl]acetic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
Chemical and physical data
FormulaC21H15ClF3NO2
Molar mass405.80 g·mol−1
3D model (JSmol)
  • C1=CC(=CC(=C1)Cl)C2=NC(=CC(=C2)CC3=CC=C(C=C3)CC(=O)O)C(F)(F)F
  • InChI=1S/C21H15ClF3NO2/c22-17-3-1-2-16(12-17)18-9-15(10-19(26-18)21(23,24)25)8-13-4-6-14(7-5-13)11-20(27)28/h1-7,9-10,12H,8,11H2,(H,27,28)
  • Key:LTSUMTMGJHPGFX-UHFFFAOYSA-N

References

edit
  1. ^ "Zatolmilast - Tetra Therapeutics". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Blauvelt A, Langley RG, Gordon KB, Silverberg JI, Eyerich K, Sommer MO, et al. (December 2023). "Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review". Dermatology and Therapy. 13 (12): 3031–3042. doi:10.1007/s13555-023-01054-3. PMC 10689637. PMID 37924462.